Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease).
Two Alzheimer's patients with disabling depression failed to respond to standard antidepressants but improved with a monoamine oxidase inhibitor. The author points out that the cholinergic system is involved in Alzheimer's symptoms and that demented patients have high monoamine oxidase levels.
D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000150:complications* / Q000523:psychology; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008995:Monoamine Oxidase / Q000097:blood; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D008995:Monoamine Oxidase